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Abstract—Mining high-order drug-drug interaction (DDI) in-
duced adverse drug effects from electronic health record (EHR)
databases is an emerging area, and very few studies have
explored the relationships between high-order drug combina-
tions. We investigate a novel pharmacovigilance problem for
mining directional DDI effects on myopathy using the FDA
Adverse Event Reporting System (FAERS) database. Our work
provides information on the risk of myopathy associated with
adding new drugs on the already prescribed medication, and
visualizes the identified directional DDI patterns as user-friendly
graphical representation. We utilize the Apriori algorithm to
extract frequent drug combinations from the FAERS database.
We use odds ratio (OR) to estimate the risk of myopathy
associated with directional DDI. We create a tree-structured
graph to visualize the findings for easy interpretation. Our
method confirmed myopathy association with previously reported
HMG-CoA reductase inhibitors like rosuvastatin, fluvastatin,
simvastatin and atorvastatin. New, previously unidentified but
mechanistically plausible associations with myopathy were also
observed, such as the DDI between pamidronate and levofloxacin.
Additional top findings are gadolinium-based imaging agents,
which however are often used in myopathy diagnosis. Other
DDIs with no obvious mechanism are also reported, such as that
of sulfamethoxazole with trimethoprim and potassium chloride.
This study shows the feasibility to estimate high-order directional
DDIs in a fast and accurate manner. The results of the analysis
could become a useful tool in the specialists’ hands through an
easy-to-understand graphic visualization.
Index Terms—Directional effect, high-order drug interaction,
FAERS, Apriori, frequent itemsets
I. INTRODUCTION
Drug interactions occur when the substances of multiple
medicines affect one another changing the effect of one or
more co-administered drugs. One emerging topic in drug
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safety research is the investigation of possible drug-drug
interactions (DDIs) causing adverse drug events (ADEs).
Acquiring knowledge about the possible adverse effects due
to drug co-administration can provide useful information for
clinical applications, drug development, the control of the
ADE-associated medical cost, and safeguarding the patients’
wellbeing. In polypharmacy situations, the information about
potential DDIs becomes crucial since the harm caused by the
concomitant drug administration could outweigh the benefits.
Polypharmacy is quite common with 25-50% of patients aged
75 years or older being exposed to at least five drugs [1].
Research on ADE detection can be broadly classified into
two categories. The first category discovers ADE patterns
via analyzing health record databases [2]–[13]. For example,
Harpaz et al. [4] performed a bi-clustering analysis on the data
from the Food and Drug Administration (FDA) Adverse Event
Reporting System (FAERS) to identify drug groups that share
common ADEs. Tatonetti et al. [8] analyzed the FAERS data
and identified 171 DDIs for eight ADEs. The second category
predicts DDI patterns via integrating biochemical and drug
target data [14], [15]. For example, Zhang et al. [14] presented
an effective ensemble learning method for DDI prediction
using a collection of drug data including drug substructure,
target, enzyme, transporter, pathway and other relevant data.
Ning et al. [15] developed a classification method to predict
DDIs associated with an ADE using drug similarity measures
constructed from drug properties and DDI patterns. In this
work, we focus on the first category of the ADE research. In
this category, most prior studies examined the effects of single
drugs (e.g., [2]–[5]) or two-way DDIs (e.g., [5]–[13]).
The investigation of DDIs involving three or more drugs
(called high-order DDIs in this work) is still an under-
explored area, partially due to the computational challenge
it is facing. Since studying high-order DDIs is important,
especially in situations like polypharmacy, this topic has
attracted a few recent attentions [5], [16], [17]. For example,
Harpaz et al. [5], [16] applied an association rule mining
algorithm to the FAERS data for revealing associations of
multiple drugs to multiple ADEs. Similar to conventional
DDI studies, they estimated the overall effect of a drug set.
However, this approach does not allow the exploration of the
relative risk between drug combinations. With this observation,
we introduce the concept of directional DDI effects, defined
as the ADE risk induced by adding one or more drugs into an
existing drug combination. In a prior study [17], we developed
an approach to identify directional effects of high-order DDIs,
which was restricted to the study of adding one drug at a time
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2to an existing drug combination. Clearly, this method does not
apply to general cases of prescribing multiple additional drugs.
To bridge this gap, in this work, we aim to extend the above
method to estimate the risk of an ADE associated with adding
one or more drugs to an existing drug combination.
II. OBJECTIVE
Our objective is to examine the DDI induced ADE risk,
and to investigate a novel pharmacovigilance topic where one
or more drugs are added concurrently on top of the current
medication. Given two sets of drug combinations DC1 and
DC2 (superset of DC1), we introduce a new concept of the
directional DDI effect from DC1 to DC2, which is defined as
the altered ADE risk associated with the change from taking
DC1 to taking DC2. Although DC2 can contain any number
of drugs, in this work, we restrict DC2 to contain up to three
drugs while DC1 up to two drugs. Thus, we are able to observe
the directional effect caused to a patient's medication, by the
addition of not only one but up to three drugs at a time. To
measure the ADE risk, we use the odds ratio (OR). As seen
in previous studies [17], [18], a restriction of this analysis
is the low frequency drug combinations. Including such drug
combinations in the analysis would result in misleading OR
estimations. To avoid such inaccuracies, we employ a data
mining technique to exclude the infrequent drug combinations
from our analysis and only focus on the analysis of frequent
drug combinations. We calculate the OR of the ADE for
adding one, two, or three drugs in the patients’ medication
and visualize the results as an intuitive tree.
To demonstrate the proposed strategy, we analyze data from
the publicly available Food and Drug Administration (FDA)
Adverse Event Reporting System (FAERS) [19]. The widely
used FAERS, is a valuable source of information about ADEs.
Specifically, we use FAERS to examine the risk of DDI
induced myopathy.
Myopathy is unexpected muscle toxicity with primary
symptoms that of muscle weakness, pain, and even tissue
break down. The prevalence of drug-induced myopathies, one
of the most common causes of muscle diseases, has been
estimated to be more than 2,000 per 100,000 individuals in
the Western Hemisphere [20]. Myopathy has been mainly as-
sociated with statin medication, and is one of the major reasons
of statin-medication discontinuation [21]–[24]. Based on the
Side Effect Resource (SIDER) database [25], among the 99
registered myopathy-related drugs, 8% are statins. In addition
to statins, glucocorticoid-induced myopathy due to decreased
protein synthesis and increased rate of protein catabolism,
has also been observed [26]. We study the proposed novel
pharmacovigilance problem, using myopathy as a testbed.
III. MATERIALS AND METHODS
A. Data preparation
Our analysis is based on the publicly available FAERS data
collected between Q1 2004 and Q3 2012. Before its structure
update in 2013, FAERS was based on case reports, containing
one or more reports for each individual, submitted at different
time points. In our analysis, we only retained the most recent
report for each individual. The processed FAERS data contain
4,077,447 ADE reports, and 1,763 FDA approved drugs. After
processing the original FAERS dataset, we created a dataset
where each record is a report containing the administered
drugs and the ADEs. To avoid the confusion between a
cause and a bystander, in our analysis, only the primary
and secondary suspects were included, and drugs labeled
as “concomitant” or “interacting” were excluded. A record
containing myopathy as an ADE was labeled as myopathy; and
otherwise as non-myopathy. Out of 4,077,447 events, there are
136,860 myopathy events. In our data, the number of drugs in
a record ranges from 1 to 103. We only extracted the frequent
drug combinations, based on which, we calculated directional
DDI effects. Fig. 1 shows the flowchart of our analysis.
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Fig. 1. Flowchart of the analysis process: Odds Ratios (ORs) are estimated
for each of the following directional drug interaction types: (1) baseline to
1-drug, (2) baseline to 2-drugs, (3) baseline to 3-drugs, (4) 1-drug to 2-drugs,
(5) 1-drug to 3-drugs, and (6) 2-drugs to 3-drugs.
B. Directional drug interaction effects
We define the directional DDI effect as the ADE risk change
introduced by adding new drugs to an existing drug combina-
tion. We use the odds ratio (OR) as a measure of the ADE risk
(see Table I). Here, individuals with myopathy are considered
as cases whereas, individuals without myopathy are considered
as controls. The OR is calculated as the ratio of odds of
the exposed individuals with myopathy over the odds of the
exposed individuals without myopathy. Exposed individuals
are defined as those who take a specific drug combination
D1, . . . , Di, Di+1, . . . , DN ; while unexposed individuals are
those taking D1, . . . , Di but not taking at least one of the
Di+1, . . . , DN . For example, the odds of taking ABC over
the odds of taking C gives the directional effect of adding AB
to C. To calculate the OR of myopathy for individuals taking
a drug combination ABC versus those taking only C, we set
the exposed group to be those who take any drug combination
containing ABC and the unexposed group to be those who take
any drug combination containing C but not ABC together (i.e.,
C, CA, or CB).
3TABLE I
CONTINGENCY TABLE FOR CALCULATING THE ODDS RATIO OF THE
DIRECTIONAL DRUG INTERACTION DC1 → DC2 :
ORDC1→DC2=(ad)/(bc), WHERE DC1 = {D1, . . . , Di} AND
DC2 = {D1, . . . , Di, Di+1, . . . , DN}.
Exposure to
drug Combination Myopathy Non-
Myopathy Total
D1, . . . , Di, Di+1, . . . , DN a b a+b
D1, . . . , Di without taking
at least one of the c d c+d
Di+1, . . . , DN
Total a+c b+d a+b+c+d
C. Extraction of frequent itemsets
The existing low-frequency drug combinations would re-
sult in misleading OR results. To exclude these infrequent
combinations, we applied the Apriori algorithm [27]. Apriori
is a data mining technique used for identifying frequent
itemsets and association rules in transactional data sets. Using
a bottom-up approach, the algorithm starts by identifying all
frequent one-element itemsets. All the frequent itemsets are
extended one item at a time to form new candidate itemsets,
given that the subsets of a frequent itemset must also be
frequent. The occurrence of each candidate itemset is counted
using the database to identify frequent ones. This procedure
continues until no new extension can be found.
In the processed FAERS data set, a record can be considered
as a transaction and a drug combination as an itemset. In
Fig. 2, a simple flowchart of the algorithm is presented. For
each of the drug combinations (itemsets), the number of its
occurrences (support) is calculated. Given a user-specified
minimum support (MinSup), a drug combination is frequent,
if it appears at least as many times as the MinSup value.
Apriori was applied using the arules package in R. In this
work, Apriori identified 764 frequent 1-drug combinations,
7,036 frequent 2-drug combinations and 4,280 frequent 3-drug
combinations.
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Fig. 2. Flowchart of the main steps of the Apriori algorithm [27].
D. Identifying drug interactions
For each frequent drug combination DC2, containing up to
three drugs, and each of its subset DC1 (i.e., DC1 ⊂ DC2),
we calculate the OR of the myopathy risk associated with
the directional DDI from DC1 to DC2. For convenience, we
call DC1 as baseline if DC1 is empty (i.e., none of the DC2
drugs are in DC1). Specifically, the OR is calculated based
on the formula OR = ad/bc (see Table I) for the following
directional effects: 1) baseline to 1-drug, 2) baseline to 2-
drugs, 3) baseline to 3-drugs, 4) 1-drug to 2-drugs, 5) 1-drug
to 3-drugs, and 6) 2-drugs to 3-drugs. Here, a represents the
count of frequent myopathy itemsets containing all the drugs
in DC2, b is the count of frequent non-myopathy itemsets
containing all the drugs in DC2, c represents the count
of frequent myopathy itemsets containing all the drugs in
DC1, and d is the count of frequent non-myopathy itemsets
containing all the drugs in DC1.
Because the myopathy events in our data constitute only
3.5% of all the ADEs, there are drug combination instances
where the number of non-myopathy events far exceeds the
number of the myopathy events. A big disproportionality
between the case and control number could be another source
of unreliable OR results. To address this issue, we set an addi-
tional constraint regarding the minimum acceptable number of
cases (exposed and unexposed myopathy events). Under these
two constraints, we estimate all possible directional effects
related to the subsets of each frequent drug set containing up
to 3 drugs. For example, for a three-drug set ABC, we calculate
the OR for each of the following directional effects:
1) Baseline → ABC
2) A→ ABC
3) B → ABC
4) C → ABC
5) AB → ABC
6) AC → ABC
7) BC → ABC
The results are corrected for multiple comparisons (Bonfer-
roni correction) and ordered by their ORs.
E. Visualization of directional drug interactions
Let S be a frequent drug set and C = {x | x ⊆ S} be
the set of all of its subsets. Given S, we can generate a
tree to organize and visualize all possible directional DDIs
between relevant sets in C. Specifically, each node represents
a drug combination. An edge from the node DC1 to the node
DC2 \ DC1 indicates the directional DDI of DC1 → DC2,
where DC1 ⊂ DC2 ⊆ S. D3: Data-Driven Documents
(http://d3js.org/) is used to plot such a tree. Examples of tree
visualization are shown in Figs. 3-6. The value shown on each
node indicates the OR of the myopathy risk associated with
taking the drug(s) on the current node in addition to the drug(s)
on the previous node. The node size is proportional to the OR,
while the node color indicates the significance of the OR, after
Bonferroni correction (white for non-significant and blue for
significant). The text color indicates the effect type (green for
OR<1 and red for OR>1).
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Fig. 3. Tree visualization for all possible directional DDI effects related to the
subsets of {pamidronate, zolipidem, zoledronate}. The value shown on each
node indicates the OR of the altered myopathy risk associated with taking the
drug(s) on the current node in addition to the drug(s) on the previous node.
A larger node size corresponds to larger OR. The node color indicates the
significance of the OR, after Bonferroni correction (white for non-significant
and blue for significant). The text color indicates protective or risk effect
(green for OR<1 and red for OR>1).
IV. RESULTS
A. Data summary
The processed FAERS dataset used, contains 4,077,447
records, among which 136,860 are myopathy events, and
3,940,587 are non-myopathy ones. From the 1,763 different
drugs in the dataset, 75 have myopathy-related effects. We
applied Apriori [27] to our data by setting MinSup=1,000,
and we identified 764 frequent single drugs, 7,527 frequent
drug pairs, and 4,280 frequent drug triplets.
B. Drug Interactions
The top 100 results for single drug versus baseline, are
shown in Table S1, with OR values ranging from 5.57 to 2.18.
The top drug is gadoteridol with OR=5.57, meaning that the
odds of myopathy in patients taking gadoteridol is 5.57 times
higher than in patients not taking it. Nicorandil, ranked ninth
in the list, is a vasodilator used for treating angina pectoris.
In 2014, specific batches of this drug were withdrawn from
the market after FDAs decision. Although, myopathy is not
one of its known side effects, cases of weakness have been
reported.
For two-drugs versus the baseline, the top 100 results
are shown in Table S2. The OR values vary from 21.56 to
7.63. The top result here is the combination of simvastatin
and clarithromycin with OR=21.56. Second and third in the
list are the simvastatin-cyclospirine and the pamidronate-
levofloxacin combinations, with OR values 17.69 and 16.36
respectively. Also, the combination of azithromycin and zole-
dronate (ranked 4th), shows an OR of 15.86. All these results
are statistically significant, after correcting for multiple com-
parisons.
TABLE II
TOP 10 OR RESULTS FOR 3-DRUG COMBINATION VS. BASELINE: WITH
BONFERRONI CORRECTION, A SIGNIFICANT p IS ≤1.17E-05.
Drug OR 95%CI p-value
Oxycodone, Zoledronate,
Levofloxacin 19.51 (17.16, 22.16) 4.89E-315
Pamidronate, Acetaminophen,
Gabapentin 18.32 (16.14, 20.78) 0.00E-00
Acetaminophen, Zoledronate,
Levofloxacin 17.01 (15.09, 19.16) 0.00E-00
Oxycodone, Zoledronate,
Gabapentin 16.84 (15.07, 18.8) 0.00E-00
Zoledronate, Dexamethasone,
Gabapentin 16.75 (14.77, 18.97) 9.31E-293
Pamidronate, Zoledronate,
Zolipidem 15.92 (14.05, 18.02) 4.63E-282
Pamidronate, Zoledronate,
Gabapentin 15.70 (14.01, 17.57) 0.00E-00
Acetaminophen, Zoledronate,
Gabapentin 15.53 (13.93, 17.28) 0.00E-00
Pamidronate, Acetaminophen,
Furosemide 14.98 (13.11, 17.10) 3.41E-237
Pamidronate, Acetaminophen,
Warfarin 14.85 (13.03, 16.88) 3.54E-247
Table II presents the top 10 findings of comparing drug
triplets with the baseline. The OR estimates range from 19.51
to 14.85. Most of the results here are similar to those of
Table S2 with the addition of pain reliever (oxycodone or
acetaminophen) or gabapentin (which may also be used to treat
neuropathic pain). For example, the top result is the combina-
tion of oxycodone, zoledronate and levofloxacin (OR=19.51).
A similar combination also appears in the comparison of
drug pairs to the baseline. Specifically, it was estimated that
individuals taking both zoledronate and levofloxacin have an
OR=12.61, which is the 11th highest OR (Table S2). We
also observe a statistically significant risk of myopathy when
zoledronate (belonging to the bisphosphonates drug class and
used to treat bone diseases) is administered with pamidronate
and zolpidem (Fig. 3). Based on the FAERS data, the risk
of myopathy when co-administering these drugs, is 15.92 (p-
value<1.17e-05; right hand side of inequality is the Bonferroni
p-value threshold. See Table II). To the best of our knowledge,
there is neither any previous study nor any report indicating an
interaction between these drugs (mild myalgia is an ADE of
zoledronate). Also, in our results, dexamethasone is frequently
implicated in the risk of myopathy by interacting with drugs
like gabapentin-zoledronate (Fig. 4), levofloxacin-zoledronate,
and lorazepam-zoledronate. Again, to our knowledge, there
are not known interactions between these individual drugs
and dexamethasone. The ORs of myopathy when comparing
each of these 3-drug combinations to the risk of only taking
dexamethasone are 16.76, 13.34 and 12.12 respectively.
For two-drug versus one-drug combinations (Table S4),
some results confirm the well-studied association between the
CYP3A and statins. Specifically, we observe a statistically
significant OR of 20.21 when adding simvastatin on top
of cyclosporine (ranked 4th with p-value < the Bonferroni
threshold of 3.59e-06) and when adding simvastatin on top
of clarithromycin (ranked 9th with OR=13.50 and p-value <
the Bonferroni threshold of 3.59e-06). The OR values of this
5TABLE III
TOP 10 OR RESULTS FOR 3-DRUG COMBINATION VS. 1-DRUG: WITH
BONFERRONI CORRECTION, A SIGNIFICANT p IS ≤3.90E-06.
3-Drug
Combination 1-Drug OR 95%CI p-value
Gadobenate
Dimeglumine, Gadobenate
Gadodiamide, Dimeglumine 20.31 (12.98, 33.40) 4.81E-84
Gadoversetamide
Gadobenate
Dimeglumine,
Gadodiamide, Gadobenate
Gadopentetate Dimeglumine 19.63 (12.54, 32.27) 7.43E-82
Dimeglumine
Gadobenate
Dimeglumine, Gadobenate
Gadopentetate Dimeglumine 18.71 (12.27, 29.79) 8.67E-85
Dimeglumine,
Gadoteridol
Gadobenate
Dimeglumine, Gadobenate
Gadodiamide, Dimeglumine 17.91 (11.83, 28.22) 1.48E-83
Gadoteridol
Zoledronate,
Dexamethason, Dexamethason 16.76 (14.67, 19.12) 7.09E-
280
Gabapentin
Gadobenate
Dimeglumine, Gadobenate
Gadoteridol, Dimeglumine 16.18 (10.90, 24.88) 1.11E-81
Gadoversetamide
Gadobenate
Dimeglumine,
Gadopentetate Gadobenate
Dimeglumine, Dimeglumine 16.16 (10.75, 25.25) 2.61E-78
Gadoversetamide
Zoledronate,
Dexamethasone, Doxorubicin 16.05 (13.54, 18.98) 3.53E-
169
Doxorubicin
Zoledronate,
Dexamethasone, Dexamethasone 13.34 (11.59, 15.34) 1.08E-
207
Levofloxacin
Gadobenate
Dimeglumine,
Gadopentetate Gadoteridol 13.06 (6.72, 29.02) 1.13E-28
Dimeglumine
Gadoteridol
table range from 28.21 to 6.73, with the top result (OR=28.21)
being that of gadobenate dimeglumine and gadopentetate
dimeglumine versus gadobenate dimeglumine.
Tables III and IV present the top 10 results of drug triplets
versus one drug and two drugs respectively. In Table III, the
OR values range from 20.31 to 13.06, with the gadolinium
contrast agents occupying the top positions, while in Table IV
the OR values range from 34.43 to 11.22.
C. Visualization of directional drug interactions
An important aspect of this study is the extended visualiza-
tion of the DDI that allows tracking down the whole DDI path
of the final result. For an n-drug combination (D1, . . . , Dn),
we start from a baseline node (none of D1, . . . , Dn are taken)
and we generate all possible paths up to n-drugs along with
the corresponding ORs. For example, for the zoledronate-
pamidronate-zolpidem combination, a tree visualization of all
TABLE IV
TOP 10 OR RESULTS FOR 3-DRUG VS. 2-DRUG COMBINATIONS: WITH
BONFERRONI CORRECTION, A SIGNIFICANT p IS ≤4.06E-06.
3-Drug 2-Drug
Combination Combination OR 95%CI p-value
Potassium Potassium
Chloride, Chloride, 34.43 (6.02,
1365.53)
9.22E-12
Sulfamethoxazole,
Trimethoprim
Trimethoprim
Acetaminophen, Chlorhexidine,
Chlorhexidine, Hydrocodone 23.86 (6.37, 199.86) 5.34E-14
Hydrocodone
Zoledronate, Dexamethason,
Dexamethason, Furosemide 12.73 (10.26, 15.84) 9.02E-
141
Furosemide
Prochlorperazine, Prochlorperazine,
Zoledronate, Dexamethasone 12.56 (9.86, 16.08) 2.16E-
113
Dexamethasone
Omeprazole, Omeprazole,
Potassium, Clavulanate 12.10 (4.00, 59.79) 3.70E-10
Clavulanate
Sulfamethoxazole, Sulfametho-
Acetaminophen, xazole 12.01 (3.99, 59.23) 2.36E-10
Hydrocodone Hydrocodone
Lorazepam,
Zoledronate, Lorazepam, 11.53 (9.29, 14.34) 1.19E-
130
Dexamethasone Dexamethasone
Salmeterol,
Valsartan, Salmeterol, 11.49 (3.08, 96.46) 4.05E-07
Fluticasone Valsartan
Propionate
Zoledronate,
Dexamethason, Dexamethason, 11.33 (9.08, 14.15) 1.99E-
107
Doxorubicin Doxorubicin
Morphine,
Zoledronate, Morphine, 11.22 (8.86, 14.28) 3.38E-
111
Dexamethason Dexamethason
the directional DDIs is presented in Fig. 3. For patients at the
baseline (none of the 3 drugs are taken), the OR of myopathy
when adding zoledronate is 2.4, indicating that zoledronate is a
risk factor (red color). Notice that, for the baseline individuals
who are prescribed simultaneously zolpidem and zoledronate,
the OR is higher (OR=9.83), as indicated by a larger node
in the graph. If now, on top of zoledronate, we prescribe
pamidronate, the OR becomes 2.55 (baseline → zoledronate:
2.4→ pamidronate: 2.55). A similar example is also presented
in Fig. 4. Given the path baseline → dexamethasone: 1.17
→ zoledronate, gabapentin: 16.76, we observe 17% increase
in the risk of myopathy for patients who take dexamethason
compared to those in the baseline, while the OR is 16.76 when,
on top of dexamethasone, we add zoledronate and gabapentin.
Similarly, we can follow any path in the graph to gradually
understand the impact of each drug (or drug combination) on
the myopathy risk.
V. DISCUSSION
A. Novelty and Contributions
In general, the majority of the studies published in this area,
are focusing on examining interactions between two drugs.
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Fig. 4. Tree visualization for all possible directional DDI effects related to
the subsets of {dexamethasone, gabapentin, zoledronate}. The value shown on
each node indicates the OR of the altered myopathy risk associated with taking
the drug(s) on the current node in addition to the drug(s) on the previous node.
A larger node size corresponds to larger OR. The node color indicates the
significance of the OR, after Bonferroni correction (white for non-significant
and blue for significant). The text color indicates protective or risk effect
(green for OR<1 and red for OR>1).
However, in cases of polypharmacy, we need to get estimations
of higher order interactions. Here, we have estimated a newly
proposed directional risk of myopathy as a result of high order
DDI, based on the FAERS dataset.
We have extended our previous work [17], by removing the
restriction imposed on the risk estimation of adding one drug at
a time to an existing combination. We illustrated our method-
ology by estimating the OR of directional effects resulting
from adding up to three drugs at a time. We also expanded
the user-friendly visualization to accommodate general DDI
patterns. In addition, we accounted for multiple comparison
correction, which was neglected in [17]. Of note, although
our prior study investigated a similar problem, the analysis
was done on different data set with a smaller number of drugs.
Furthermore, we substituted an in-house R implementation
of Apriori used in our previous study [17], by a more efficient
Apriori implementation in R package “arules”, which signifi-
cantly improved the computational time. Specifically, in Du et
al. [17], the experiments were performed on a Linux Xeon 64-
bit dual CPU workstation, and the computation of all frequent
3-drug combinations using a dataset of 6,388,674 events and
212 drugs, took 312.9 hours for MinSup=1, 36.4 hours for
MinSup=200, and 6.5 hours for MinSup=1,000. In this work,
with the new implementation, our experiments were performed
on a Windows 10 Enterprise 64 bit desktop with an Intel(R)
Core(TM) i5-7500 CPU. We were able to obtain all frequent
3-drug combinations for a dataset of 4,077,447 events and
1,763 drugs, in 17.2 seconds for MinSup=1, 8.9 seconds for
MinSup=200, and 8.4 seconds for MinSup=1,000. To obtain
all frequent 2-drug combinations, it took 8.2 seconds for any
MinSup ranging from 1 to 1,000.
Ibrahim et al. [28] and Li et al. [29] also analyzed FAERS
data but focused on two-way drug interactions. Cai et al. [30]
examined the adverse effect induced by three co-administered
drugs (similar to our baseline versus 3-drug combination
effect) in the FAERS data, while they did not investigate the
directional DDIs. To the best of our knowledge, our work is the
first study offering estimates on high-order directional DDIs
using the FAERS data.
Below, we discuss our findings, grouped into several cat-
egories: (1) gadolinium-based imaging agents and drugs as-
sociated with diagnosis or treatment of myopathy, (2) known
myotoxic drugs or drugs with interactions known to increase
the risk of myopathy, (3) previously unidentified but mecha-
nistically plausible interactions, and (4) previously unidentified
interactions with no obvious mechanism for increasing the risk
of myopathy.
B. Drugs associated with diagnosis and treatment of myopa-
thy
The data in the FAERS reports do not provide the ability
to evaluate the timing of drugs with respect to the ADE
manifestation. Therefore, drugs used for the diagnosis and
treatment of myopathy, not just those that could be potentially
causative, may be highly associated with the ADE. The top
two agents (both gadolinium-based contrast agents) associated
with myopathy were gadoteridol and gadoversatimide (Table
S1). Two other gadolinium compounds (gadodiamide and
gadobenate dimuglumine) were also in the top 10 and top
20 myopathy-associated drugs respectivelly (Table S1). These
agents have been reported to cause muscular calcification and
weakness, which may present as myopathy [31]. However,
MRI is often a part of the diagnostic work-up of patients
presenting with myopathy. Therefore, it is likely that the high
association between myopathy and gadolinium-based contrast
agents is due to their use in the diagnosis of myopathy. How-
ever, this does not necessarily explain why a myopathy report
would be associated with multiple gadolinium-based contrast
agents nor why individuals exposed to multiple contrast agents
are at increased risk of myopathy (Tables S4 and III).
This same conclusion may be made for other drugs with
high OR for myopathy, such as chlorhexidine (Table S1 and
S2), a topical antiseptic that may have been applied prior to
muscle biopsy. We also note a number of pain relievers (e.g.
oxycodone, acetaminophen, hydrocodone) among the 2-drug
and 3-drug combinations associated with increased myopathy
risk. While there is some evidence of myopathy with high
doses of these drugs [32], the use of these agents to relieve
myopathy symptoms cannot be ruled out.
C. Drugs or drug interactions previously reported to increase
myopathy risk
The presence of drugs or drug interactions that have been
previously reported to increase myopathy risk substantiates.
Most noticeably, a number of HMG-CoA reductase inhibitors
(Table S1) were observed to increase the risk of myopathy
over baseline, including rosuvastatin (OR=4.59 Table S1),
fluvastatin (OR=4.29, Table S1), simvastatin (OR=3.98, Table
S1) and atorvastatin (OR=3.85, Table S1). We also identified
increased OR for myopathy with other lipid lowering agents,
7such as gemfibrozil, ezetimibe, and colesevelam. Muscle pain,
weakness, and myopathy have been reported with these drugs,
and they are also known to increase the risk of statin-induced
myopathy. Our analyses also identified a number of DDIs
known to increase the risk of myopathy through well-defined
mechanisms. For instance, clarithromycin and cyclosporine
are known to inhibit metabolism and transport, respectively,
of many statin drugs, including simvastatin [33] (Table S2).
This leads to increased plasma concentrations of the statin
and higher risk for myopathy [34], [35]. Additional DDIs
previously linked to myopathy, which were captured by our
analysis and were highly ranked, include atorvastatin with
rosuvastatin, simvastatin with gemfibrozil and rosuvastatin
with simvastatin (7th, 12th and 16th highest OR respectively,
Table S2).
In order to investigate how many of the known myopathy-
related findings coincide with our results, we searched the
OFFSIDES and TWOSIDES databases (both developed by
Tatonetti et al. [7]). Our analysis captured almost 92% of
the drugs in OFFSIDES, that were linked to the events of
myopathy toxic and myopathy steroids (all have significant p-
values). In the TWOSIDES database, no events were found
under the term “myopathy”. Hence, we focused on myopathy-
related events. Specifically, we searched for 2-drug inter-
actions linked to muscle weakness, rhabdomyolysis, muscle
disorder, muscle paresis, muscle spasm, muscle inflammation,
musculoskeletal pain, myasthenia gravis, muscle strain, and
muscle rupture. TWOSIDES contains 32,304 unique 2-drug
combinations related to the aforementioned events. From these
drug combinations, 2,906 are among our 2-drug vs. baseline
results. The ORs of myopathy in our analysis for these
drug combinations range from 21.56 (i.e., for (simvastatin,
clarithromycin)) to 0.08 (i.e., for (capecitabine, cisplatin)).
While the statin interactions are widely known to be impli-
cated to myopathy events and are the top interactions identified
among our results, it warrants further investigation to build a
complete collection of every known DDI related to myopathy.
An important future direction is to perform a comprehensive
curation of relevant literature, based on which an unbiased
estimate of our method’s sensitivity can be obtained.
D. Previously unidentified but mechanistically plausible inter-
actions
Although myalgia has been reported as an adverse event for
the bisphosphonate pamidronate, there is no literature evidence
regarding the mechanism of the effect. However, renal toxicity
has been associated with pamidronate. In turn, renal failure
is associated with an increased risk of myopathy. Thus, it
may be hypothesized that the increased risk of myopathy with
pamidronate (OR=3.59 compared to baseline; Table S1), is
likely secondary to renal failure. This hypothesis is further
strengthened by the increased risk of myopathy observed when
pamidronate is found in combination with other nephrotoxic
drugs (e.g. OR of pamidronate with levofloxacin is 16.36 over
baseline; Table S2; Fig. 5).
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Fig. 5. Tree visualization for all possible directional DDI effects related to
the subsets of {pamidronate, levofloxacin}. The value shown on each node
indicates the OR of the altered myopathy risk associated with taking the
drug(s) on the current node in addition to the drug(s) on the previous node.
A larger node size corresponds to larger OR. The node color indicates the
significance of the OR, after Bonferroni correction (white for non-significant
and blue for significant). The text color indicates protective or risk effect
(green for OR<1 and red for OR>1).
E. Previously unidentified interactions with no obvious mech-
anism for increased risk of myopathy
Our analysis identified several drugs and drug combinations
with high OR for myopathy not supported by previous studies,
e.g. sulfamethoxazole with trimethoprim and potassium chlo-
ride (Table IV; Fig. 6). Another one is that of azithromycin
with zoledronate (Table S2). The mechanism for increased
risk of myopathy for these drugs or drug pairs is unclear and
requires further investigation.
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Fig. 6. Tree visualization for all possible directional DDI effects related to the
subsets of {Sulfamethoxazole, Potassium Chloride, Trimethoprim}. The value
shown on each node indicates the OR of the altered myopathy risk associated
with taking the drug(s) on the current node in addition to the drug(s) on the
previous node. A larger node size corresponds to larger OR. The node color
indicates the significance of the OR, after Bonferroni correction (white for
non-significant and blue for significant). The text color indicates protective or
risk effect (green for OR<1 and red for OR>1).
VI. CONCLUSIONS
Through this work, we were able to get directional high-
order drug interactions in a computationally efficient way,
by applying the Apriori algorithm for frequent itemset iden-
tification. We calculated the OR for the directional adverse
effect of myopathy for up to three drugs at a time. Our
findings confirmed well-known adverse effects of specific drug
combinations, revealed new but plausible associations, but
also identified drug combinations with no profound mecha-
nism but warranting further investigation. Despite the valuable
knowledge hidden in the FAERS data, there is no information
8about the elapsed time from the drug administration until the
adverse effect manifestation. The absence of temporal relation
information, between the exposure and the event, complicates
the inference process, by introducing higher uncertainty. Thus,
it is more difficult to decide whether an observed association
could potentially be causal or due to pre-existing myopathy.
Examples of this phenomenon are the findings related to
gadolinium compounds, and a series of pain relievers. Despite
this limitation, we were able to confirm drug interactions
previously associated to myopathy and also reveal new drug
combinations with a plausible underlying mechanism for
causing myopathy. The current methodology can be extended
to higher order drug combinations (e.g., >3 drugs), with
affordable computational cost and accurate risk estimation.
That, combined with the interactive visual representation could
be a valuable tool in the specialists hands, not only for ensuring
patients health but also for promoting drug research.
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